Jonathan D. (Jon ) Campbell, PhD, is the Chief Science Officer (CSO) of the National Pharmacerutical Council (NPC), which sponsors and conducts research on health policy issues related to the development and use of innovative biopharmaceuticals to improve the health of patients. As CSO, Dr. Campbell leads NPC's research agenda in consert with NPC's board and research team. As a research and advocate for improving the U.S. healthcare system through sustainable access and biopharmaceutical innovation, Dr. Campbell is dedicated to conducting research that helps decision-makers understand the tradeoffs and consequences of health policies that impact patient access to treatments and the ecosystem of biopharmaceutical innovation. Dr. Campbell shaped his career within academics. After training at the University of Washington, he joined the faculty at the University of Colorao Anschutz Medical Campus, earning multiple appointments in Pharmacy and Public Health from 2009-2020. During his academic career, Dr. Campbell gained insights on the work of biopharmaceutical manufacturers through a summer internship at Novartis in Basel, Switzerland (2004) and expanded his research and training network through a sabbatical in Budapest, Hungary with Syreon Research Institute (2018). Prior to joining NPC, Dr. Campbell served as Senior Vice President for Health Economics at the Institute for Clinical and Economic Review (ICER), where he made contributions to ICER assessments and their value assessment methodology. Dr. Campbell is an author of over 250 manuscripts and abstracts and holds an adjunct faculty appointment within the Center for Evaluation of Value and Risk in Health at Tufts University School of Medicine. Dr. Campbell's training includes graduate degrees in pharmaceutical outcomes research (PhD) and biostatistics (MS) from the University of Washington. He graduated Phi Beta Kappa with Bachelor of Arts degrees in mathematics and chemistry from St. Olaf College.